SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.55-5.5%Jan 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jinping Shi who wrote (3895)9/24/1997 3:32:00 PM
From: aknahow   of 17367
 
Good to see you back. Forgot mention that Xoma says DSMB will review again after 130 people have been treated. So need 50 more to get to that point from the 80 number st released.Perhaps from a business point of view it is better that the trials have continued. As some of your past post have indicated the determination of statistical significance is complex but the larger the sample the less doubt will exist as what the results actually mean.

Even when the sample is large as in the CORR drug, great debate can rage over the significance of less than strong results. Therefore, perhaps more is better since even "strong" results with a small sample might not seem important to many market players as indeed was the case with the open trial of just 26.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News